

ORGANISATION AFRICAINE DE LA PROPRIETE INTELLECTUELLE
(O.A.P.I.)

(19)



(11) N°

010311

(51) Inter. Cl.⁶

A61K 31/19

(12) BREVET D'INVENTION

(21) Numéro de dépôt: 60888

(22) Date de dépôt: 16.09.1996

(30) Priorité(s): U.K.
17.03.1994 N° 9405292.5
Turkey
18.05.1994 N° 94/393

(24) Délivré le: 07.10.1997

(45) Publié le: 07 OCT. 1997

(73) Titulaire(s):

RADOPATH LIMITED
P.O.Box 687, 4 Wests Centre,
St.Helier, Jersey,
Channel Islands

(72) Inventeur(s):

Dr. Washington Odur AYUKO
25 Sundridge Road, Kingstanding,
Birmingham B44 4NY (England)


(74) Mandataire: CABINET J. EKEME
B.P. 6370
YAOUNDE - Cameroun

(54) Titre: Anti-viral and anti-cancer agents.

(57) Abrégé:

2-chloro-5-nitrobenzoic acid and various other chloro and nitro substitute benzoic acid derivatives are disclosed for administration in tablet or injectable solution form for the prophylaxis and therapy of neoplasm or viral infection. The active compounds have surprising efficacy in various treatment regimes and have particular application to HIV-infection and demonstrate various beneficial effects, including regression of lesions in HIV-related Kaposi's sarcoma.


FIG.1
AZT AND ddCyd
INTERNAL
CONTROLS



ANTI-VIRAL & ANTI-CANCER AGENTS

The present invention relates to arylating agents, in particular phenylating agents, which are suitable as therapeutic compounds, especially in the treatment of cancer and disease caused by viral infections (eg retrovirus infections such as HIV. As shown by studies reported herein, the compounds of the invention show marked anti-tumour activity and in AIDS and pre-AIDS therapy show the capacity to regress Kaposi's sarcoma, improve CD4 count in humans, increase the level of various blood parameters in murine patient models and to achieve weight gain and general patient condition by action against HIV and/or its effects (eg opportunistic disease).

According to the invention, there is provided a compound of the following general formula for use in the treatment of prophylaxis or therapy of neoplasm or viral infection such as HIV-infection:-



wherein X_1 and X_2 are, each independently, hydrogen or chloro and wherein X_3 and X_4 are, each independently, hydrogen or nitro, provided that at least two of X_1 , X_2 , X_3 and X_4 are other than hydrogen, or a salt or ester thereof (eg a salt wherein $-COOH$ is substituted by $-COOR$ in which R is optionally substituted amino).

Conveniently, X_1 is chloro, X_2 is chloro or hydrogen, X_3 is nitro and X_4 is nitro or hydrogen. The following are preferred compounds:-

2, 4-dichloro-3, 5-dinitrobenzoic acid

4-chloro-3, 5-dinitrobenzoic acid

- 2-chloro-3, 5-dinitrobenzoic acid
- 2-chloro-5-nitrobenzoic acid
- 2, 5-dichlorobenzoic acid
- 2, 4-dinitrobenzoic acid
- 5 3, 5-dinitrobenzoic acid
- 2, 5-dichloro-4-nitrobenzoic acid
- 2, 4-dichloro-5-nitrobenzoic acid
- 2, 6-dichloro-4-nitrobenzoic acid
- 3, 5-dichloro-4-nitrobenzoic acid
- 10 4-chloro-3-nitrobenzoic acid
- 2-chloro-4-nitrobenzoic acid
- 3, 4-dichlorobenzoic acid

Since treatment in accordance with the invention is by what is believed to be an
15 arylating mechanism, use is typically at relatively high concentrations and, consequently, doses. Generally, the recommended dosage is 1mg/kg body weight to 30mg/kg body weight per day for 5 days weekly.

The compounds of the invention may be prepared by known process techniques for
20 preparing benzene substituted compounds. Such techniques are described in various standard texts, for example, "Organic Syntheses" 1963 Collective Volume 4, pages 364 to 366, by Harry P Schultz and published by John Wiley and Sons Inc. Post-preparation sterilization may be required, at least following formulation of the compounds into pharmaceutical composition form.

25

The compounds of the invention may be formulated for use as pharmaceutical compositions (eg for iv, ip, oral or sc administration) comprising at least one active compound and a diluent or carrier. Thus, the invention includes a pharmaceutical composition, which composition comprises a compound according to the invention
30 and a pharmaceutically-acceptable diluent or carrier (eg aqueous).

Such a composition may be in bulk form or, more preferably, unit dosage form. Thus, for example, the composition may be formulated as a tablet, capsule, powder, solution or suspension. Soft gel capsules may be especially convenient. The composition may be a liposomal formulation or administered in a slow sustained release delivery system.

Compositions in accordance with the invention may be prepared using the active compounds defined herein in accordance with conventional pharmaceutical practice. The diluents, excipients or carriers which may be used are well known in the formulation art and the form chosen for any particular regimen will depend on the given context and the physician's choice.

Thus, for example, as illustrated below the compounds of the invention may be administered in solution in sterile deionised water. Also, if necessary, solution may be facilitated using dimethyl sulphoxide (DMSO) or alternatively an alcohol, a glycol or a vegetable oil. The compounds are most favourably administered in corn oil or as a solution in DMSO/sterile water. In the case of the use according to the invention of sodium salts of the active compounds, the active ingredient is preferably administered as an aqueous solution.

In using a compound of the invention, dosage guidance can be taken from animal studies such as that described below. In such studies doses of from about 50mg/kg typically up to about 1000mg/kg (eg up to about 400mg/kg, conveniently about 200mg/kg or less). Thus it is to be expected that a typical dosage for humans will be from about 5mg/kg upwards (eg up to about 20mg/kg). The concentration and dose are to be sufficient to bring an arylating mechanism into play. For intravenous administration the active compound will be dissolved or dispersed in an aqueous or other injectable liquid bearing in mind the aforementioned requirements of dosage. Typically, concentration will be 250mg/ml or less. Patient tolerance was found to be of a higher order for concentrations below that threshold although concentrations of more than 250mg/ml may be used. Typically, a preferred concentration is less than 100mg/ml, with concentrations below 50mg/ml (eg 40mg/ml) being preferred. For

oral administration, enteric coated tablets will often be preferred. Maximum strength will be less than 500mg and preferably 400mg or less. Thus, for example, a range of strengths for oral administration (whether in tablet or other solid form) will be 100mg, 200mg or 400mg. Patients who are subject to oral administration will generally fast for 8 hours prior to first dose with the fast continuing for 4 hours after first dose. Free access to fluid will generally be allowed during this fasting period. Intravenous treatment will generally take place by administration very slowly over a period, typically a period of approximately 20 minutes or more. Administration will typically be by catheter, for example a catheter left in situ after flushing with 2ml of saline. Of course, the catheter will in practice then be used for taking blood samples for pharmacokinetic measurements and removed prior to the patient's departure from the clinic.

As shown by the results reported in Table 6 below, 2-chloro-5-nitrobenzoic acid shows considerable anti-tumour activity in vivo. This could not be supported in vitro and it appears some compounds according to the invention require activation in the patient's liver. This and some other compounds may also be immunomodulators.

The following animal study illustrates the remarkable activity of compounds of the invention.

ANIMAL STUDIES

The in vivo anti-tumour responses of various compounds according to the invention were assessed against the ascitic tumours, MAC15A murine colon adenocarcinoma and various solid tumour models. The MAC15A ascites tumour cells were transplanted into male NMR1 mice by ip inoculation at a cell density of 1×10^5 cells in 200 μ l buffer (Table 1). The solid tumour models included the MAC13 and MAC16 murine colon adenocarcinomas, the B16 F1 murine melanoma and the M5076 reticulum cell sarcoma.

5 The animals were located in both cases into groups of 5 to 8 animals.

10 Except where otherwise stated, the compounds used were dissolved in DMSO and diluted in sterile distilled water, at appropriate concentrations before administration in a solvent volume of 200µl. Anti-tumour responses were obtained by comparing the median survival times or tumour growth inhibition against solvent controls. The results obtained are as shown in Tables 1 to 6 below.

Preparation of dosage solutions is exemplified as follows:-

Dosage: 50mg/kg weight per animal per day thus 1.1mg per mouse per day

Total Formulation: 10ml solvent plus 55mg for division into 50 doses of 1.1mg
dissolves in 200µl solvent

T/C%

T/C% is determined as follows:-

5	Animal Survival	<u>Test</u>	<u>Control</u>
		T days	C days

$$T/C\% = \frac{T}{C} \times 100$$

10

Example

15

Animal Survival	<u>Test</u>	<u>Control</u>
	443 days	100 days

$$T/C\% = \frac{443}{100} \times 100 = 443$$

20

A figure of 158 or above indicates performance justifying clinical trial.

Conclusions

25

The effect of a group of compounds on the growth rate of a number of experimental tumours has been evaluated in vivo and the following findings were noted:-

30

1. Structure-activity relationships against the MAC15A murine colon adenocarcinoma, in the female NMRI mice showed maximal activity on a split-dose schedule and when the halogen was maximally activated for nucleophilic attack.
2. Against the M5076 reticulum cell sarcoma, 2, 4-dichloro-3, 5-dinitrobenzoic acid showed activity on a split-dose schedule down to 25mg/kg body weight by both ip and sc routes. Both the amide and the methyl ester showed 10-fold increase in

toxicity and were without anti-tumour activity. The acid also effectively inhibited growth of B16 murine melanoma and the MAC16 murine colon adenocarcinoma.

It is concluded that this group of compounds show a wide spectrum of activity against murine models.

TABLE 1

Anti-tumour activity against MAC15A (murine adenocarcinoma colon). 5 animals per group. Dose 100mg kg⁻¹ ip per day.

Code	Compound	Schedule (days)	T/C% ^a
15 C4	4-chloro-3, 5-dinitrobenzoic acid	1, 2, 3, 4, 5	271
C1	2, 4-dichloro-3, 5-dinitrobenzoic acid	1, 2	243
C12	2, 5-dichlorobenzoic acid	1, 2, 3, 4, 5	171
C28	2, 4-dinitrobenzoic acid	1, 2, 3, 4, 5	100
C29	3, 5-dinitrobenzoic acid	1, 2, 3, 4, 5	100

a = median, T-test group, C-solvent control

TABLE 2

Anti-tumour activity against M5076-reticulum cell sarcoma 16 days after im transplant. 7 animals per group. Drugs dissolved in corn oil. Dosage is per day.

5					
	Compound	Dose (mg/kg)	Route	Schedule (days)	% Tumour Weight Inhibition
10	2, 4 BA	75 ^a	ip	1, 4, 6, 9	79, 88 ^b
		50	ip	1, 4, 6, 9	57
		25	ip	1, 2, 4, 6, 9	75
		75	sc	1, 4, 5, 7, 9	66
		50	sc	1, 2, 4, 5, 6, 7, 9	76
		25	sc	1, 2, 4, 5, 6, 7, 9	63
15	2, 4 BM	1.0 ^a	ip	1, 2, 3, 4, 5, 6, 7, 8, 9	41
		0.5	ip	1, 2, 3, 4, 5, 6, 7, 8, 9	39
		0.25	ip	1, 2, 3, 4, 5, 6, 7, 8, 9	42

20 a = Maximum tolerated dose

b = Two independent experiments; 4 animals had no tumour in the second experiment

2, 4 BA = 2, 4-dichloro-3, 5-dinitrobenzoic acid (C1)

2,4 BM = 2, 4-dichloro-3, 5-dinitrobenzoic acid methyl ester (C3)

25

% Tumour Weight Inhibition:-

Treated

Control

Agm

Bgm

Tumour weight

30 % inhibition = $\frac{B - A}{B} \times 100$

B

TABLE 3

Anti-tumour activity against B16F1-murine melanoma 12 days after sc transplant. 6 animals per group. Drugs dissolves in corn oil. Dosage is per day.

	Compound	Dose (mg/kg)	Route	Schedule (days)	% Tumour Weight Inhibition
10	2, 4 BA	75 ^a	ip	1, 5	71, 81 ^b
		50	ip	1, 5	45, 56 ^b
		25	ip	1, 5	13
		75	sc	1, 3, 5	30
		50	sc	1, 3, 5	9
		25	sc	1, 3, 5	22
15	4 BA	100	ip	1, 5	39
		75	ip	1, 5	41
		50	ip	1, 5	10
20	4 BM	2.5 ^a	ip	1, 3	67
		1.25	ip	1, 2, 3	43

a = Maximum tolerated dose

b = Two independent experiments

25

2, 4 BA = 2, 4-dichloro-3, 5-dinitrobenzoic acid (C1)

4BA = 4-chloro-3, 5-dinitrobenzoic acid (C4)

4 BM = 4-chloro-3, 5-dinitrobenzoic acid methyl ester (C6)

30

TABLE 4

Anti-tumour activity against MAC13 murine colon adenocarcinoma 12 days after im transplant. Drugs dissolved in corn oil. Dosage is per day.

5	Compound	Dose (mg/kg)	Route	Schedule (days)	% Tumour Weight inhibition
	2, 4 BA	75 ^a	ip	1, 4, 5	45
	2, 4 BA	50	ip	1, 2, 3, 4, 5, 6, 7, 8, 9	39
10	2, 4 BA	graph ¹	ip	graph ¹	graph ¹
	2 BA	graph ²	ip	graph ²	graph ²

a = Maximum tolerated dose

15

2, 4 BA = 2, 4-dichloro-3, 5-dinitrobenzoic acid¹ (C1)

2 BA = 2-chloro-5-nitrobenzoic acid (C17)

(1: see Figure 2 of the drawings; 2: see figure 3 of the drawings)

20

TABLE 5

Anti-tumour activity against MAC16, murine colon adenocarcinoma sc transplanted on day 11 after the beginning of treatment with 2, 4-dichloro-3, 5-dinitrobenzoic acid (2, 4 BA; C1). Drug dissolved in corn oil. The tumour volumes were at least 40mm³ at the beginning of the treatment. 6 animals per group. Dosage is per day.

25

25	Compound	Dose (mg/kg)	Route	Schedule (days)	% Tumour Weight Inhibition
	2, 4 BA	75 ^a	ip	1, 2, 5, 8	88
30		50	ip	1, 2, 4, 5, 8	91

a = Maximum tolerated dose

TABLE 6

Anti-tumour activity of C17 against B16 murine melanoma 12 days after sc transplant
 5 on female C57/black mice. 6 animals per group. Dosage is per day and is ip.

	Code	Compound	Dose	Schedule	% Tumour Weight
			(mg/kg)	(days)	Inhibition
10	C17	2-chloro-5-nitrobenzoic acid	700	1, 2, 3, 4, 5, 6	62

Anti-tumour activity and toxicity studies have additionally been completed for the
 15 following compounds with broadly satisfactory results:-

- C22 2, 5-dichloro-4-nitrobenzoic acid
 C23 2, 4-dichloro-5-nitrobenzoic acid
 C24 2, 6-dichloro-4-nitrobenzoic acid
 20 C26 2-hydroxy-5-nitrobenzoic acid
 C27 3, 5-dichloro-4-nitrobenzoic acid

In addition, the following primary assay was used to investigate the anti-viral activity
 of compounds in accordance with the invention.

25

Primary Assay

- (i) *Acute Infection Assay.* High titre virus stocks of the human immunodeficiency virus HIV-1_{RF} were grown in H9 cells with RM1 1640 (Flow laboratories) supplemented with 10% fetal calf serum, penicillin (100IU/ml). Cell debris was
 30 removed by low speed centrifugation, and the supernatant stored at -70°C until required. In a typical assay C8166 T-lymphoblastoid CD4+ cells were incubated with 10xTCID50 HIV-1_{RF} at 37°C for 90 minutes and then washed three times with

phosphate buffered saline (PBS). Cell aliquots (2×10^5) were resuspended in 1.5ml growth medium in 6ml tubes, and active compounds in log dilutions [200 μ M to 0.2 μ M] were added immediately. 20mM stock solutions of each compound were made up in 70% alcohol. The compounds were stored as a powder and made up
5 freshly in distilled water before each experiment or were stored as a 90 mM stock solution in 70% alcohol. The final concentration of alcohol in the tissue culture medium was 1%. The cells were then incubated at 37°C in 5% CO₂. At 72 hours post-infection 200 μ l of supernatant was taken from each culture and assayed for HIV (Kingchington et al, 1989, Robert et al 1990) using an antigen capture ELISA which
10 recognizes all the core proteins equally (Coulter Electronics, Luton, UK). The following controls were used: supernatants taken from uninfected and infected cells, infected cells treated with AZT (Roche Products UK Ltd) and ddC (Roche) and RO31-8959 (Roche) an inhibitor of HIV proteinase. The IC₅₀ activities of 8959, AZT and ddC in infected cells were 1, 10, 20 nM and 200nM respectively (accompanying
15 Figure 2). The ELISA plates were read with a spectrophotometer. Compounds were tested in duplicate at each concentration, and the data shown is the average of at least two assays. This assay assesses the activity of compounds by measuring their inhibition of HIV core antigen levels.

20 (ii) *Chronically Infected Cell Assay.* Chronically infected cells (H9rf) were washed three times to remove extracellular virus and incubated with the active compounds (200-0.2 μ M) for four days. HIV-1 antigen in the supernatant was then measured using an ELISA.

25 To test for compound toxicity, uninfected H9 cells were incubated with the compounds for four days. Supernatants were discarded and the cells resuspended in 200 μ l pg growth medium containing ¹⁴C protein hydrolysate. After 6 hours the cells were harvested and the ¹⁴C incorporation measured.

30 (iii) *Toxicity Assay.* To test for compound toxicity, aliquots of 2×10^5 of uninfected cells were cultured with the compounds in the same dilutions for 72 hours. The cells were then washed with PBSA and resuspended in 200 μ l of growth medium

containing ^{14}C protein hydrolysate. After 12, hours the cells were harvested and the ^{14}C incorporation measured. Uninfected, untreated cells were used as controls. Toxicity is expressed as inhibition of uptake of ^{14}C protein hydrolysate.

- 5 The results of these assays are summarized in Table 7 below. The IC_{50} is the drug concentration that causes a 50% reduction in HIV core antigen levels as detected by the Coulter P24 antigen assay and is determined by doubling dilutions of supernatant taken from tubes containing untreated acutely infected cells. The CD_{50} is the concentration of drug that causes a 50% inhibition of cells as measured by ^{14}C protein
10 hydrolysate uptake. The therapeutic index (TI) is determined by dividing the CD_{50} by the IC_{50} .

TABLE 7

15	<u>Code</u>	<u>Compound</u>	<u>IC_{50}</u>	<u>CD_{50}</u>	<u>TI</u>
	C4	4-chloro-3, 5-dinitrobenzoic acid	30 μm	70 μm	2.33

Following the same methodology, more extensive assays were performed as reported
20 in Tables 8 below.

25

30

TABLE 8.1

STRUCTURE ACTIVITY RELATIONSHIP AGAINST HIV VIRUS

5	CODE	COMPOUNDS
	C1	2, 4-dichloro-3, 5-dinitrobenzoic acid
	C3	2, 4-dichloro-3, 5-dinitrobenzoic acid methyl ester
	C4	4-chloro-3, 5-dinitrobenzoic acid
10	C6	4-chloro-3, 5-dinitrobenzoic acid methyl ester
	C7	2-chloro-3, 5-dinitrobenzoic acid
	C8	2-chloro-3, 5-dinitrobenzoic acid methyl ester
	C9	4-chloro-3-nitrobenzoic acid
	C10	2-chloro-4-nitrobenzoic acid
15	C11	3, 4-dichlorobenzoic acid
	C12	2, 5-dichlorobenzoic acid
	C17	2-chloro-5-nitrobenzoic acid

20

TABLE 8.2

		IC50 (Antiviral)	CC50 (Toxicity)	SI (Selectivity Index)
	<u>Against HIV-I IIIB</u>			
25	C1	5	70	14
		36	70	2
		33	70	2
		35	60	2
	Average	27	70	3
30	C1	10	30	3
		2.5	20	8

Against HIV-IRF

	C1	7	60	8.5
		-	-	56
		16	56	3.5
5	Average	11.5	57	5

Against Chronically infected cells

	C1	16	30	2
		16	95	6
10	Average	16	63	4

Against HIV-1-IIIB

	C2	2	70	35
	C3	0.3	7	23
	C4	40	100	2.5
15		30	70	2.3
	Average	35	85	2.4
	C5	5	50	10
	C6	5	60	12
	C7	23	150	6
20		5	>200	>10
	Average	22	>175	8
	C7	>1	35	>35
		10	30	3
	C8	10	60	5
25	C9	>200	>200	-
	C10	>200	>200	-
	C11	>200	>200	-
	C12	>200	>200	-

Against HIV-I IIIB

30	C17	>1	>1000	>1000
		5	>1000	>200

Patient Tests

A pilot study was conducted for safety, pharmacokinetics and preliminary activity of C17 in patients with HIV-1 infection and HIV-related Kaposi's sarcoma. In the pilot study, 10 patients were enrolled but only 6 were eligible for evaluation. These patients were positive for serum antibody to HIV-1 as determined by both enzyme-linked immunosorbent assay (ELISA) and Western Blot. These patients had WHO Clinical Stage 2 to 3 for HIV infection and disease and fulfilled the inclusion and exclusion criteria as per the Clinical Trial Protocol. Their CD4 ranged from 0.072 to 0.812 x 10³ cells/mm³ (normal range 1.0 x 1.3 x 10³ cells/mm³). Patient 6 had AIDS-related Kaposi's sarcoma confirmed on histology.

C17 was prepared for intravenous administration under GMP (good manufacturing practice) in strength of 40 mg/ml following the method set forth below for producing a 250mg/ml solution, additional water being added at Step 7:-

Method of Preparation

1. To 275ml water for injection add 266.4ml 4N sodium hydroxide solution and mix.
2. Add with stirring 182.5g of active compound.
3. Add additional 4N sodium hydroxide if needed to obtain solution.
4. Filter solution through a Sterivex GV 0.22µm filter.
5. Dilute to approximately 680ml with water for injection.
6. Adjust to pH 7.2-7.6 with hydrochloric acid.
7. Make-up to 730ml water for injection. Adjust pH if necessary.
8. Transfer solution to aseptic room and filter through Sterivex GV 0.22µm filter into injection vials. Seal with rubber stoppers and aluminium closures.
9. Effect terminal sterilization by autoclave.

The patients received 10mg/kg body weight/day of C17 by deep intramuscular injection daily for 5 days weekly. The CD4 counts were estimated before and at about 2 weeks after the beginning of the therapy.

- 5 The CD4 counts in all 6 patients showed an increase which was associated with clinical improvements in patient general condition including weight gain and a marked decrease in opportunistic infections and diarrhoea. Patient observations are shown in Tables 9 below.
- 10 In the case of Patient 6, the sarcoma lesions disappeared.

Murine Haematology

- 15 Preliminary data on the administration of C17 in mice and rats showed increases in red blood cell count, haemoglobin concentration, macrophage count, white blood cell count (WBC), lymphocyte count and haematocrit (HTC) on day 7 when maximum tolerated dose (MTD) was given by 5 consecutive daily intravenous injections. These values returned to normal on day 14. The MTD values were 950mg and 900mg/kg body weight/day respectively in mouse and rat. The data are reported in Figures 4 to
- 20 11.

TABLE 9.0 (Summarizing Tables 9.1 to 9.6)

PATIENTS 1 TO 6 IMMUNOLOGY:-

PATIENT 1	2		3		4		5		6	
	Before	After	Before	After	Before	After	Before	After	Before	After
Lymphocytes x $10^3/\text{mm}^3$	2.1	2.0	2.0	1.9	0.9	1.1	1.8	2.0	2.1	1.9
CD4 %	19	38	18	27	8	17	6	22	33	23
CD4 ABS/ mm^3	0.399	0.760	0.360	0.513	0.072	0.187	0.108	0.440	1.023	0.437
CD8 ABS/ mm^3	0.567	0.840	0.940	0.874	0.270	0.682	1.350	1.260	1.550	0.931
CD4/CD8	0.70	0.90	0.38	0.59	0.27	0.27	0.08	0.35	0.66	0.47

010311

TABLE 9.1

PATIENT 1 IMMUNOLOGY:-

	DAY	1	20
5	Lymphocytes x 10^3mm^{-3}	2.1	2.0
	CD4 %	19	38
10	CD4 ABS/ mm^3	0.399	0.760
	CD8 ABS/ mm^3	0.567	0.840
	CD4/CD8	0.70	0.90
15			

TABLE 9.2

PATIENT 2 IMMUNOLOGY:-

	DAY	1	14
20	Lymphocytes x 10^3mm^{-3}	2.0	1.9
	CD4 %	18	27
25	CD4 ABS/ mm^3	0.360	0.513
	CD8 ABS/ mm^3	0.940	0.874
30	CD4/CD8	0.38	0.59

TABLE 9.3

PATIENT 3 IMMUNOLOGY:-

	DAY	1	20
5	Lymphocytes x 10^3mm^{-3}	0.9	1.1
	CD4 %	8	17
10	CD4 ABS/ mm^3	0.072	0.187
	CD8 ABS/ mm^3	0.270	0.682
15	CD4/CD8	0.27	0.27

TABLE 9.4

PATIENT 4 IMMUNOLOGY:-

	DAY	1	14
20	Lymphocytes x 10^3mm^{-3}	1.8	2.0
	CD4 %	6	22
25	CD4 ABS/ mm^3	0.108	0.440
	CD8 ABS/ mm^3	1.350	1.260
30	CD4/CD8	0.08	0.35

TABLE 9.5

PATIENT 5 IMMUNOLOGY:-

	DAY	1	21
5	Lymphocytes x 10^3mm^{-3}	2.8	3.1
	CD4 %	29	33
10	CD4 ABS/ mm^3	0.812	1.023
	CD8 ABS/ mm^3	1.456	1.550
	CD4/CD8	0.56	0.66
15			

TABLE 9.6


PATIENT 6 IMMUNOLOGY:-

	DAY	1	34
20	Lymphocytes x 10^3mm^{-3}	2.1	1.9
	CD4 %	18	23
25	CD4 ABS/ mm^3	0.378	0.437
	CD8 ABS/ mm^3	1.218	0.931
30	CD4/CD8	0.31	0.47

Claims

1. A compound of the following general formula for use in the treatment of prophylaxis or therapy of neoplasm or viral infection:-

5



10

wherein X_1 and X_2 are, each independently, hydrogen or chloro and wherein X_3 and X_4 are, each independently, hydrogen or nitro, provided that at least two of X_1 , X_2 , X_3 and X_4 are other than hydrogen, or a salt or ester thereof.

15 2. A compound as claimed in Claim 1 wherein X_1 is chloro, X_2 is chloro or hydrogen, X_3 is nitro and X_4 is nitro or hydrogen.

3. A compound as claimed in Claim 2 wherein X_1 and X_2 are other than 4-chloro.

20 4. A compound as claimed in Claim 1 or Claim 2 wherein X_1 and X_2 together represent 2-chloro-, 4-chloro-, 2,5-dichloro-, 2, 4-dichloro-, 2, 6-dichloro-, 3, 5-dichloro- or 3, 4-dichloro- and wherein X_3 and X_4 together represent two hydrogen atoms, 3-nitro-, 4-nitro-, 5-nitro-, 2, 4-dinitro- or 3, 5-dinitro-, provided that:-

25 (i) when X_3 and X_4 together represent 3, 5-dinitro-, X_1 and X_2 together represent 2-chloro-,

(ii) when X_3 and X_4 together represent 5-nitro-, X_1 and X_2 together represent 2-chloro- or 2, 4-dichloro-,

(iii) when X_3 and X_4 together represent two hydrogen atoms, X_1 and X_2 together represent 3, 4-dichloro-,

30

(iv) when X_3 and X_4 together represent 4-nitro-, X_1 and X_2 together represent 2, 5-dichloro-, 3, 5-dichloro-2-chloro- or 2, 6-dichloro-,

(v) when X_3 and X_4 together represent 3-nitro-, X_1 and X_2 together represent 4-chloro-.

5 5. A compound as claimed in Claim 4 wherein X_1 , X_2 , X_3 and X_4 are as there defined subject to provisos (i), (ii), (iv) and (v) and subject to the further proviso that when X_3 and X_4 together represent 5-nitro-, X_1 and X_2 together represent 2, 4-dichloro-.

10 6. A compound as claimed in Claim 1 and as set forth by name below or an ester or salt thereof:-

- 6.1 2, 4-dichloro-3, 5-dinitrobenzoic acid
- 6.2 4-chloro-3, 5-dinitrobenzoic acid
- 6.3 2-chloro-3, 5-dinitrobenzoic acid
- 15 6.4 2, 5-dichlorobenzoic acid
- 6.5 2, 4-dinitrobenzoic acid
- 6.6 3, 5-dinitrobenzoic acid
- 6.7 2, 5-dichloro-4-nitrobenzoic acid
- 6.8 2, 4-dichloro-5-nitrobenzoic acid
- 20 6.9 2, 6-dichloro-4-nitrobenzoic acid
- 6.10 3, 5-dichloro-4-nitrobenzoic acid
- 6.11 4-chloro-3-nitrobenzoic acid
- 6.12 2-chloro-4-nitrobenzoic acid
- 6.13 3, 4-dichlorobenzoic acid
- 25 6.14 2-chloro-5-nitro-benzoic acid.

7. A pharmaceutical composition for use in the treatment by prophylaxis or therapy of neoplasm or viral infection, the composition comprising a compound as claimed in any preceding claim together with a pharmaceutically-acceptable carrier or
30 diluent.

8. A composition as claimed in Claim 7 wherein the carrier is a solid excipient or the carrier or diluent is aqueous.
9. A composition as claimed in Claim 7 or Claim 8 and comprising 2-chloro-5-nitrobenzoic acid, or a salt or ester thereof, encapsulated by a soft gel capsule or contained by a sustained release drug delivery system.
10. A method of preparing a pharmaceutical composition as claimed in Claim 7 or Claim 8 which method comprises combining a compound as claimed in any one of Claims 1 to 6 with aqueous sodium hydroxide solution to form a solution, adjusting the pH of the solution to an alkaline pH of not more than 8 by addition to the solution of an acidic material, optionally diluting the pH-adjusted solution with physiologically injectable water and sterilising the solution.
11. Use of a compound as claimed in any one of Claims 1 to 6 for the preparation of a medicament for the treatment by prophylaxis or therapy of neoplasm or viral infection in mammalian subjects.
12. Use of a compound as claimed in any one of Claims 1 to 6 for the treatment of Kaposi's sarcoma.
13. Use of a compound as claimed in any one of Claims 1 to 6 for the preparation of a medicament for the treatment of Kaposi's sarcoma.
14. A pharmaceutical composition in the form of enteric coated tablets comprising a compound as claimed in any one of Claims 1 to 6 in strength 100 to 400mg, the compound being formulated as a mixture comprising the compound together with an inert pharmaceutically-acceptable solid tableting carrier.

010311

FIG.1
AZT AND ddCyd
INTERNAL
CONTROLS





FIG. 2
 Effect against MAC13 Murine Colon
 Adenocarcinoma Transplanted
 S C 6 animals per group



010311

FIG.3

Effect against MAC 13 Murine Colon
Adenocarcinoma Transplanted
SC 6 animals per group




FIG. 4

Effect of C17 on rat Hemaglobin
after 3 and 7 days





FIG.5

Effect of C17 on rat RBCs after
3 and 7 days



010311




FIG.7

Effect of C17 on mouse macrophages
after 7 and 14 days




FIG.8

Effect of C17 on mouse WBCs and

lymphocytes after
7 and 14 days





FIG. 9

Effect of C17 on mouse HCT
after 7 and 14 days



010311

FIG.10

Effect of C17 on mouse Hemaglobin levels at 7days and 14days

 Hb / DAY 7
 Hb / DAY 14
 * SIGNIFICANT




FIG.11

Effect of C17 on mouse RBCs
after 7 and 14 days

▨ RCB/DAY 7
▤ RCB/DAY 14
* SIGNIFICANT

